Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinsos disease
The first three weeks were completely uneventful
It is important to tell your doctor about any heart problems you have now or may have had in the past
Sulfur is a sticky (and smelly) molecule that acts somewhat like flypaper, attracting and binding to bad stuff like free radicals, toxins, and dirty estrogens
Retatrutide generally has the stronger weight-loss narrative because its metabolic research profile and headline efficacy data are much more aggressive
Emerging Therapy Retatrutide Retatrutide is a new emerging (LY-3437943) is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under trial conducted by Eli Lilly and Company Mechanism of Action GIP agonism enhances insulin release, suppresses appetite, inhibits fat accumulation GLP-1 agonism enhances insulin release, suppresses glucagon, slows gastric emptying Glucagon receptor agonism boosts energy expenditure, supports glycemic control Collectively, it addresses glucose homeostasis, appetite regulation, energy metabolism, and weight loss Competitive Edge over Existing Therapies Superior efficacy: Around 24% weight loss surpasses GLP-1-only treatments (e.g., semaglutide, tirzepatide)
